Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20120082617Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: November 8, 2011Publication date: April 5, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20120082618Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: December 14, 2011Publication date: April 5, 2012Applicant: PROSCAN RX PHARMA INC.Inventors: CLAUDIO CUELLO, URI SARAGOVI, PIERRE DU RUISSEAU, PHIL GOLD, NICOLE BERNARD, SERGE MOFFETT
-
Patent number: 8147804Abstract: The invention relates to initial 68Ge/Ga-generator elute which is guided directly to a cation exchanger, whereon 68Ga is quantitatively absorbed and is cleaned simultaneously in a chemical and radio chemical manner. Subsequently, the 68Ga-radio nuclide is combined with a radio pharmaceutical substance by a marking precursor made of a ligand or a peptide or a protein which is cross-linked in a covalent manner to a ligand.Type: GrantFiled: November 22, 2005Date of Patent: April 3, 2012Assignee: Johannes Gutenberg-Universität MainzInventors: Frank Roesch, Dmitry V. Filosofov, Konstantin Zhernosekov, Marc Jennewein
-
Publication number: 20120076726Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.Type: ApplicationFiled: August 26, 2011Publication date: March 29, 2012Applicant: BIOARCTIC NEUROSCIENCE ABInventors: Par GELLERFORS, Lars LANNFELT, Dag SEHLIN, Frida EKHOLM PETTERSSON, Hillevi ENGLUND
-
Publication number: 20120076725Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: ApplicationFiled: January 12, 2011Publication date: March 29, 2012Applicant: CELERA CORPORATIONInventors: Charles BIRSE, Marcia LEWIS, Steve RUBEN, Mehdi MESRI
-
Patent number: 8142758Abstract: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof.Type: GrantFiled: February 18, 2005Date of Patent: March 27, 2012Assignee: Algeta ASInventors: Roy H. Larsen, Gro Salberg
-
Publication number: 20120063999Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: ApplicationFiled: April 8, 2011Publication date: March 15, 2012Applicants: Agensys, Inc., The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovitz
-
Publication number: 20120064001Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: ApplicationFiled: September 6, 2011Publication date: March 15, 2012Applicants: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.Inventors: Anita Kavlie, Kyle Schlunegger
-
Publication number: 20120064000Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: August 1, 2011Publication date: March 15, 2012Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United Sates of America, as represented by the Secretary, Department of HealthInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 8133486Abstract: The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH).Type: GrantFiled: May 10, 2004Date of Patent: March 13, 2012Assignee: MMRGLOBAL, Inc.Inventors: Daniel P. Gold, Robert J. Shopes
-
Publication number: 20120052007Abstract: The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.Type: ApplicationFiled: June 3, 2011Publication date: March 1, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Xiping Liu, Neil Desai
-
Publication number: 20120045392Abstract: A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-A? targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-A? effective to inhibit amyloid beta aggregation in the subject.Type: ApplicationFiled: April 27, 2010Publication date: February 23, 2012Inventor: Chris Dealwis
-
Publication number: 20120045390Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: September 5, 2003Publication date: February 23, 2012Applicant: Genentech, Inc.Inventors: Frederic J. DeSauvage, William I. Wood, Zemin Zhang
-
Publication number: 20120045391Abstract: The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.Type: ApplicationFiled: October 14, 2009Publication date: February 23, 2012Applicant: National Research Council CanadaInventors: Daniva Stanimirovic, Abedelnasser Abulrob, Maria Moreno
-
Patent number: 8119103Abstract: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker.Type: GrantFiled: February 20, 2007Date of Patent: February 21, 2012Assignee: Mallinckrodt LLCInventor: Dennis A. Moore
-
Publication number: 20120041303Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.Type: ApplicationFiled: August 1, 2011Publication date: February 16, 2012Applicant: THE WASHINGTON UNIVERSITYInventors: Dennis E. Hallahan, Raymond Mernaugh
-
Publication number: 20120034160Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: ApplicationFiled: August 2, 2011Publication date: February 9, 2012Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Publication number: 20120034159Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor, and the B-cell maturation (BCMA) receptor.Type: ApplicationFiled: April 19, 2011Publication date: February 9, 2012Inventor: WAYNE KINDSVOGEL
-
Publication number: 20120034161Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other a cyclooctene or cyclooctyne.Type: ApplicationFiled: April 12, 2010Publication date: February 9, 2012Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Marc Stefan Robillard, Raffaella Rossin, Johan Lub, Pascal Renart Verkerk, Dirk Burdinski
-
Publication number: 20120035529Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.Type: ApplicationFiled: September 29, 2009Publication date: February 9, 2012Inventors: George Coukos, Andrea Facciabene
-
Publication number: 20120034158Abstract: An immuno-imaging agent for the detection of tumor cells by means of an immuno-imaging technique, including at least one of: an anti-Met monoclonal antibody, a fragment of an anti-Met monoclonal antibody containing the epitope binding region thereof, a genetically engineered antibody containing the epitope binding region of an anti-Met monoclonal antibody, a humanized antibody containing the epitope binding region of an anti-Met monoclonal antibody, or combinations thereof, wherein the anti-Met monoclonal antibody is produced by the hybridoma cell line ICLC PD 05006, and corresponding compositions and kits.Type: ApplicationFiled: July 14, 2011Publication date: February 9, 2012Inventors: Paolo Maria Comoglio, Paolo Carminati, Guus Van Dongen
-
Patent number: 8110196Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.Type: GrantFiled: April 29, 2005Date of Patent: February 7, 2012Assignee: Polytopas LLCInventors: Michael W. Deem, Jeong-Man Park, Hao Zhou
-
Publication number: 20120020880Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: September 23, 2011Publication date: January 26, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S. F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Patent number: 8101155Abstract: The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein.Type: GrantFiled: January 16, 2007Date of Patent: January 24, 2012Assignee: Fred Hutchinson Cancer Research CenterInventor: Beverly Torok-Storb
-
Publication number: 20120014872Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.Type: ApplicationFiled: August 17, 2011Publication date: January 19, 2012Applicant: diaDexus, Inc.Inventors: Susana Salceda, Yongming Sun, Herve Recipon, Robert Cafferkey
-
Publication number: 20120014870Abstract: With dedicated research, the present inventors discovered that not only the LGR7 gene but also the LGR7 protein are highly expressed in clear cell adenocarcinoma cells of ovarian cancer. Furthermore, the present inventors found that anti-LGR7 antibodies have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against LGR7-expressing cells. From the above findings, the present inventors discovered that the anti-LGR7 antibodies are useful for diagnosis, prevention, and treatment of primary and metastatic ovarian clear cell adenocarcinoma.Type: ApplicationFiled: December 25, 2009Publication date: January 19, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Yuriko Uehara, Shinichi Funahashi
-
Publication number: 20120014871Abstract: The present invention provides methods and kits for identifying a cell that exhibits or is predisposed to exhibiting unregulated growth by detecting hypermethylation of a gene or a regulatory region in at least one gene in the cell. Also provided are methods for diagnosis or prognosis of ovarian cancer in a subject. Also provided are methods of ameliorating ovarian cancer in a subject by administering to the subject an agent that demethylates a hypermethylated gene or regulatory region thereof.Type: ApplicationFiled: February 26, 2010Publication date: January 19, 2012Inventors: Mohammad O. Hoque, Mariana Brait, Leonel Maldonado
-
Publication number: 20120003148Abstract: Methods and compositions are provided for treating and imaging a virus-associated cancer, where the methods comprise administering to a subject a radiolabeled binding molecule, wherein the binding molecule binds to a virus antigen expressed by virus-associated cancer cells in the subject.Type: ApplicationFiled: December 13, 2007Publication date: January 5, 2012Inventors: Ekaterina Dadachova, Arturo Casadevall, Howard Strickler, Robert D. Burk
-
Publication number: 20120003150Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.Type: ApplicationFiled: September 13, 2011Publication date: January 5, 2012Applicant: QUINTESSENCE BIOSCIENCES, INC.Inventors: Tony Klink, John Kink, Laura Strong
-
Publication number: 20120003149Abstract: [Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.Type: ApplicationFiled: February 20, 2010Publication date: January 5, 2012Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroyuki Aburatani, Hiroko Iwanari, Shunsuke Niwa, Yoshiko Nakada
-
Patent number: 8088357Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: December 1, 2003Date of Patent: January 3, 2012Assignee: Nemod Biotherapeutics GmbH & Co. KGInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
-
Publication number: 20110311443Abstract: The invention relates to a method for treating a cancerous and/or an inflammatory disease in a patient, comprising internally administering to the patient an effective amount of a pharmaceutical preparation blocking the biological activity of at least one protein cluster (CMP) or group of CMPs containing at least CD26 and/or CD29. The invention also relates to a pharmaceutical composition for the treatment of a cancerous and/or an inflammatory disease in a patient, a method for identifying a cancerous and/or an inflammatory disease in a patient, a method of identifying at least one candidate for development of anti-cancerous or anti-inflammatory agents, a use of an antibody for preparing a pharmaceutical preparation or medicament for the treatment of prostate cancer, a composition or kit comprising at least one antibody and/or at least one ligand, and a biochip.Type: ApplicationFiled: March 1, 2010Publication date: December 22, 2011Applicant: KLAUS TSCHIRA STIFTUNG GGMBHInventor: Walter Schubert
-
Publication number: 20110305630Abstract: Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein, PrP, which has been identified on various cancer cell lineages.Type: ApplicationFiled: June 24, 2011Publication date: December 15, 2011Inventor: Neil Roy CASHMAN
-
Publication number: 20110305629Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: May 17, 2011Publication date: December 15, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20110305631Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20110300067Abstract: Methods are disclosed for using agents and treatments that cause the release of melanin from melanin-containing melanomas to increase the efficacy of therapy and imaging of the melanomas with radiolabeled anti-melanin antibodies and peptides.Type: ApplicationFiled: September 2, 2009Publication date: December 8, 2011Inventors: Ekaterina Dadachova, Arturo Casadevall
-
Publication number: 20110300069Abstract: The invention concerns the use of a labelled ligand having specificity for the human CD4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of certain cell populations which comprise CD4-bearing cells in human individuals. In addition the invention concerns a composition which comprises a labelled ligand having specificity for the CD4 molecule and CD4-bearing cells or particles, and a method for determining the extent and progression of diseases in which human CD4-bearing cells are of clinical importance.Type: ApplicationFiled: August 17, 2011Publication date: December 8, 2011Applicant: BIOTECTID GMBHInventors: Frank Emmrich, Raimund W. Kinne, Rudiger Laub, Ullrich Pigla
-
Publication number: 20110300068Abstract: The present invention provides an agent for the prophylaxis or treatment of kidney cancer or urinary bladder cancer, and a diagnostic reagent for these cancers which comprise an antibody against nerve growth factor 2/neurotrophin-3 or a partial peptide thereof or a salt thereof, which antibody neutralizes nerve growth factor 2/neurotrophin-3 and does not cross-react with the Nerve Growth Factor.Type: ApplicationFiled: January 12, 2010Publication date: December 8, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuya Watanabe, Shinichi Kondo, Ryosuke Katsuyama
-
Patent number: 8071072Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: May 30, 2007Date of Patent: December 6, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu
-
Publication number: 20110293514Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.Type: ApplicationFiled: July 18, 2011Publication date: December 1, 2011Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
-
Publication number: 20110293512Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin ?v?6, and the responsiveness of patient populations to ?v?6-active compounds and compositions (e.g., antibodies and other ligands that bind ?v?6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas.Type: ApplicationFiled: April 18, 2011Publication date: December 1, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman
-
Publication number: 20110293513Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: June 20, 2011Publication date: December 1, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20110286916Abstract: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.Type: ApplicationFiled: November 16, 2009Publication date: November 24, 2011Inventors: Jose Miguel Aste-Amezaga, Ningyan Zhang, Fubao Wang, Andrew Bett, Anna Demartis, Maurizio Nuzzo, Paolo Monaci, Stephen Blacklow, Jon Aster
-
Publication number: 20110286917Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: ApplicationFiled: June 10, 2011Publication date: November 24, 2011Inventors: Gang An, Robert Veltri
-
Publication number: 20110286918Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.Type: ApplicationFiled: July 7, 2011Publication date: November 24, 2011Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans J. HANSEN
-
Publication number: 20110280801Abstract: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled by the described methods. Preferably, the F-18 may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety. Alternatively, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other embodiments, the F-18 labeled moiety may comprise a targetable construct used in combination with a bispecific or multispecific antibody to target F-18 to a disease-associated antigen, such as a tumor-associated antigen. The F-18 labeled targetable construct peptides are stable in serum at 37° C. for a sufficient time to perform PET imaging analysis.Type: ApplicationFiled: June 17, 2011Publication date: November 17, 2011Applicant: IMMUNOMEDICS, INC.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20110280800Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Applicant: ABBOTT LABORATORIESInventors: Chengbin WU, Tariq GHAYUR, Chung-ming HSIEH, Dominic J. AMBROSI
-
Publication number: 20110268656Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.Type: ApplicationFiled: December 2, 2010Publication date: November 3, 2011Inventors: David Ho, Tove Olafsen, Arye Lipman
-
Publication number: 20110268657Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: December 30, 2010Publication date: November 3, 2011Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, JR., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith